<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3644346/" ref="ordinalpos=916&amp;ncbi_uid=6078055&amp;link_uid=PMC3644346" image-link="/pmc/articles/PMC3644346/figure/F6/" class="imagepopup">Fig. 6. An illustration showing the modulation of the BRAF/MEK/ERK/RSK2 <span class="highlight" style="background-color:">signaling</span> <span class="highlight" style="background-color:">pathway</span> by silybin in SK-MEL-5 cells.  From: Direct targeting of MEK1/2 and RSK2 by silybin induces cell cycle arrest and inhibits melanoma cell growth. </a></div><br /><div class="p4l_captionBody">In melanoma, the mutation of BRAF (V600E) constitutively activates the down–stream kinase MEK1/2, which phosphorylates ERK2. Phosphorylated ERK2 activates RSK2, which transmits a signal downstream to transcription factors, such as AP-1, NF-κB and STAT3, and induces their transcriptional activity to express cyclin D1. Silybin inhibits this oncogenic signaling pathway by direct regulation of MEK1/2 and RSK2.</div></div>